Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon E Murphy

Showing results (31-40 of 140) with videos related to

Pageof 14
Sort By:
Plos One|November 22, 2013
CYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changesA Joseph Bloom, Maribel Martinez, Li-Shiun Chen, et al.
Chemical Research in Toxicology|January 31, 2016
Quantitation of the Minor Tobacco Alkaloids Nornicotine, Anatabine, and Anabasine in Smokers' Urine by High Throughput Liquid Chromatography-Mass SpectrometryLinda B von Weymarn, Nicole M Thomson, Eric C Donny, et al.
Pharmacogenetics and Genomics|December 6, 2012
Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumptionA Joseph Bloom, Sharon E Murphy, Maribel Martinez, et al.
Pharmacogenetics and Genomics|November 7, 2013
The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European AmericansA Joseph Bloom, Linda B von Weymarn, Maribel Martinez, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 3, 2007
CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanoneXiuling Zhang, Jaime D'Agostino, Hong Wu, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 19, 2008
Stability of the nicotine metabolite ratio in ad libitum and reducing smokersMarc E Mooney, Zhong-Ze Li, Sharon E Murphy, et al.
Pharmacogenetics and Genomics|January 8, 2013
A compensatory effect upon splicing results in normal function of the CYP2A6*14 alleleA Joseph Bloom, Oscar Harari, Maribel Martinez, et al.
Chemical Research in Toxicology|February 3, 2023
Quantitation of Ten Urinary Nicotine Metabolites, Including 4-Hydroxy-4-(3-pyridyl) Butanoic Acid, a Product of Nicotine 2'-Oxidation, and CYP2A6 Activity in Japanese Americans, Native Hawaiians, and WhitesLinda B von Weymarn, Xiaotong Lu, Nicole M Thomson, et al.
Plos One|May 26, 2017
Association of CYP2A6 activity with lung cancer incidence in smokers: The multiethnic cohort studySungshim L Park, Sharon E Murphy, Lynne R Wilkens, et al.
Clinical Trials (London, England)|September 14, 2020
Detecting participant noncompliance across multiple time points by modeling a longitudinal biomarkerRoss L Peterson, Joseph S Koopmeiners, Tracy T Smith, et al.
Pageof 14

Showing results (31-40 of 140) with videos related to

Sort By:
Pageof 14
Plos One|November 22, 2013
CYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changesA Joseph Bloom, Maribel Martinez, Li-Shiun Chen, et al.
Chemical Research in Toxicology|January 31, 2016
Quantitation of the Minor Tobacco Alkaloids Nornicotine, Anatabine, and Anabasine in Smokers' Urine by High Throughput Liquid Chromatography-Mass SpectrometryLinda B von Weymarn, Nicole M Thomson, Eric C Donny, et al.
Pharmacogenetics and Genomics|December 6, 2012
Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumptionA Joseph Bloom, Sharon E Murphy, Maribel Martinez, et al.
Pharmacogenetics and Genomics|November 7, 2013
The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European AmericansA Joseph Bloom, Linda B von Weymarn, Maribel Martinez, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 3, 2007
CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanoneXiuling Zhang, Jaime D'Agostino, Hong Wu, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 19, 2008
Stability of the nicotine metabolite ratio in ad libitum and reducing smokersMarc E Mooney, Zhong-Ze Li, Sharon E Murphy, et al.
Pharmacogenetics and Genomics|January 8, 2013
A compensatory effect upon splicing results in normal function of the CYP2A6*14 alleleA Joseph Bloom, Oscar Harari, Maribel Martinez, et al.
Chemical Research in Toxicology|February 3, 2023
Quantitation of Ten Urinary Nicotine Metabolites, Including 4-Hydroxy-4-(3-pyridyl) Butanoic Acid, a Product of Nicotine 2'-Oxidation, and CYP2A6 Activity in Japanese Americans, Native Hawaiians, and WhitesLinda B von Weymarn, Xiaotong Lu, Nicole M Thomson, et al.
Plos One|May 26, 2017
Association of CYP2A6 activity with lung cancer incidence in smokers: The multiethnic cohort studySungshim L Park, Sharon E Murphy, Lynne R Wilkens, et al.
Clinical Trials (London, England)|September 14, 2020
Detecting participant noncompliance across multiple time points by modeling a longitudinal biomarkerRoss L Peterson, Joseph S Koopmeiners, Tracy T Smith, et al.
Pageof 14